FDM PHARMA

FDM PHARMA has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.8m and a net result of €357,146. Equity is growing by ~28.7% per year across the filed fiscal years. Its solvency ranks better than 77% of 12331 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).